3 assets in Pituitary Gland Adenoma

Therapeutic assets addressing Pituitary Gland Adenoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Pituitary Gland Adenoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Pituitary Gland Adenoma	National Cancer Institute (NCI)	P2	CCC (53)
Panitumumab-Irdye800 Pituitary Gland Adenoma	Eben Rosenthal	Early P1	NR ()